Last updated: August 24, 2026
Dantrium is a mature dantrolene sodium brand with limited standalone financial disclosure, minimal remaining composition-of-matter protection, and demand concentrated in two markets: hospital treatment of malignant hyperthermia and chronic management of severe spasticity. Its commercial value depends less on prescription growth than on hospital stocking requirements, product availability, formulation convenience, and supply reliability.
The broader dantrolene market has two distinct segments:
| Segment |
Primary use |
Main products |
Commercial profile |
| Acute injectable |
Malignant hyperthermia emergency treatment |
Dantrium IV, Revonto, Ryanodex and generic dantrolene sodium injection |
Hospital-stocked, low-volume, high-urgency market |
| Oral capsules |
Chronic spasticity |
Dantrium capsules and generic dantrolene sodium capsules |
Mature, genericized, price-sensitive market |
Dantrium’s brand economics are constrained by generic substitution and the age of its active ingredient. The strongest commercial position in dantrolene is held by products that reduce preparation time and storage burden in operating rooms, particularly Ryanodex, rather than by traditional Dantrium capsules.
What is Dantrium and how large is its addressable market?
Dantrium contains dantrolene sodium, a direct-acting skeletal-muscle relaxant. The drug reduces calcium release from the sarcoplasmic reticulum by affecting the ryanodine receptor pathway. The FDA-approved uses include treatment and prevention of malignant hyperthermia and management of chronic spasticity associated with conditions such as spinal cord injury, stroke, cerebral palsy and multiple sclerosis.[1]
The addressable market is structurally narrow:
- Malignant hyperthermia is rare but requires immediate treatment.
- Every facility administering triggering anesthetics must maintain an adequate dantrolene supply under professional and accreditation expectations.
- Chronic spasticity generates recurring prescriptions but faces extensive generic competition.
- Injectable demand is tied to operating-room volume and hospital stocking decisions rather than routine patient incidence.
- Oral demand is more exposed to formulary restrictions and generic substitution.
Dantrium therefore has a defensive, necessity-based market rather than a conventional growth market. Hospital customers may continue purchasing the product even when annual utilization is low because treatment delay can create severe clinical and operational consequences.
How has the Dantrium financial trajectory evolved?
Dantrium’s public financial trajectory is difficult to isolate because manufacturers have generally reported it within broader pharmaceutical portfolios rather than as a separate revenue line. Public company filings do not provide a consistent, product-level Dantrium revenue series. The more supportable conclusion is that Dantrium has transitioned from an originator-led product to a mature, multi-supplier market.
Commercial trajectory by period
| Period |
Market development |
Financial effect |
| 1970s-1990s |
Dantrolene established for malignant hyperthermia and spasticity |
Originator economics and clinical familiarity supported brand value |
| 2000s |
Generic oral competition expanded |
Price pressure increased in chronic-use capsules |
| 2010-2014 |
Injectable formulation competition remained limited |
Hospital stocking and supply reliability preserved pricing power |
| 2014 onward |
Ryanodex introduced with a rapid-reconstitution formulation |
Value shifted toward convenience, operating-room readiness and differentiated delivery |
| Current market |
Multiple generic and branded injectable options coexist |
Volume is stable but revenue is fragmented and exposed to contracting |
Dantrium’s financial profile is likely characterized by relatively stable but modest demand, episodic shortages or procurement shifts, and more pronounced price competition in oral capsules than in emergency injectables. A single annual sales number for Dantrium would not accurately describe the commercial opportunity without separating oral and injectable products.
What is the FDA regulatory status of Dantrium?
Dantrium has long-standing FDA approval in oral and injectable forms. The FDA-approved label identifies dantrolene sodium as the active ingredient and includes warnings concerning hepatotoxicity, particularly with chronic oral use.[1]
FDA-approved product categories
| Product |
Dosage form |
Principal indication |
Regulatory characteristics |
| Dantrium capsules |
Oral capsules |
Chronic spasticity |
Mature product with generic substitution |
| Dantrium IV |
Powder for injection |
Malignant hyperthermia |
Emergency-use product requiring hospital inventory |
| Generic dantrolene sodium injection |
Injectable |
Malignant hyperthermia |
Competes on price, supply and reconstitution requirements |
The FDA has also approved Ryanodex, an injectable dantrolene product developed to reduce the amount of diluent and preparation time required during a malignant hyperthermia emergency.[2] This regulatory differentiation changed the competitive basis of the injectable segment.
What is the Orange Book status of Dantrium?
Dantrium’s original active-ingredient and basic product protection are historically expired. Dantrolene sodium was approved decades ago, so the brand does not have the type of remaining exclusivity associated with recently launched small-molecule medicines.
The Orange Book framework remains relevant for determining listed patents and therapeutic-equivalence status, but Dantrium’s current commercial exposure is primarily generic competition rather than a pending loss of core patent exclusivity.[3]
Exclusivity assessment
| Protection category |
Dantrium position |
| New chemical entity exclusivity |
Expired |
| Basic composition-of-matter patent |
Expired or no longer commercially relevant |
| Oral formulation protection |
No material modern barrier to generic substitution |
| Injectable formulation protection |
Core Dantrium protection is not a current moat |
| Regulatory exclusivity |
No meaningful current exclusivity expected for the legacy brand |
| Brand recognition |
Still relevant in hospital purchasing and clinical familiarity |
For business analysis, the key distinction is between Dantrium’s legacy brand identity and the broader dantrolene product market. Generic manufacturers can compete without needing to overcome a modern Dantrium patent estate.
What patents protect Dantrium and dantrolene products?
Dantrium’s original intellectual-property position has largely expired because the product was introduced in the 1970s. Current patent value in the dantrolene market is more likely to reside in differentiated injectable formulations, packaging, dosing systems and methods of preparation.
Ryanodex illustrates this shift. Eagle Pharmaceuticals developed a concentrated, rapidly reconstituted dantrolene formulation intended for malignant hyperthermia emergencies. Its commercial differentiation is based on delivery and preparation rather than a new active ingredient.[2]
Patent strength by product category
| Product category |
Patent strength |
Main competitive barrier |
| Dantrium oral capsules |
Low |
Brand familiarity and prescribing history |
| Generic oral capsules |
Very low |
Manufacturing authorization and distribution |
| Traditional injectable dantrolene |
Low to moderate |
Supply qualification, hospital contracts and inventory |
| Ryanodex-type formulation |
Moderate |
Formulation, concentration, reconstitution and device-related claims |
| Malignant hyperthermia treatment method |
Low as a standalone barrier |
Clinical protocols and regulatory labeling |
Formulation patents can support premium pricing, but they do not necessarily prevent substitution by traditional injectable products. Hospitals may weigh preparation speed against acquisition cost, inventory space, training and local protocol requirements.
When does Dantrium lose exclusivity and face generic entry?
Dantrium has already passed the principal exclusivity milestones that protect newer small-molecule drugs. Generic entry is therefore an established market condition, not a future event.
Generic entry scenarios
Oral capsules
Generic substitution is the dominant scenario. Payers and pharmacies can generally select therapeutically equivalent dantrolene sodium capsules when available and approved. Brand Dantrium may retain limited demand among prescribers or patients with historical familiarity, but the product lacks a strong economic basis for premium pricing.
Traditional injectable products
Generic entry is more complicated operationally. A hospital may prefer a lower-cost injectable product but still require:
- Confirmed availability during anesthesia procedures
- Adequate shelf-life and inventory rotation
- Staff familiarity with reconstitution
- Compatibility with malignant hyperthermia protocols
- Reliable distribution during shortages
These factors can preserve customer retention after patent expiry.
Differentiated rapid-reconstitution products
Ryanodex and similar products face substitution from conventional dantrolene injections, but the comparison is not purely price-based. Preparation time, vial count, storage footprint and emergency workflow can justify a premium in some institutions.
Which companies compete with Dantrium?
The competitive landscape includes legacy brand suppliers, generic manufacturers and differentiated injectable developers.
| Company or product |
Role in market |
Competitive basis |
| Dantrium |
Legacy dantrolene brand |
Brand recognition and established labeling |
| Generic dantrolene manufacturers |
Oral and injectable competition |
Price, supply and contract access |
| Revonto |
Injectable dantrolene product |
Established malignant hyperthermia use |
| Ryanodex, Eagle Pharmaceuticals |
Rapid-reconstitution injectable |
Lower preparation burden and concentrated presentation |
| Hospital wholesalers and group purchasing organizations |
Procurement channel |
Contract pricing and supply reliability |
The most important competitive distinction is not whether a product contains dantrolene. It is whether the product can meet hospital emergency-use requirements at an acceptable total cost.
How strong is the Dantrium patent estate?
Dantrium’s current patent estate is weak by branded-pharmaceutical standards. Its active ingredient is old, its therapeutic uses are established, and generic competition is already present.
Factors weakening Dantrium’s patent position
- The product’s original approval dates to the 1970s.
- Core composition and basic use patents are no longer commercially protective.
- Generic dantrolene products have entered both oral and injectable categories.
- The market’s main differentiation now comes from formulation and supply-chain execution.
- Hospital purchasing decisions can shift rapidly when products experience shortages or contract changes.
Factors supporting residual brand value
- Clinician familiarity with the Dantrium name.
- Inclusion in established malignant hyperthermia protocols.
- Existing distribution relationships.
- Customer reluctance to change emergency-stock products without operational review.
- Potential value in reliable supply during market shortages.
The commercial moat is therefore operational, not primarily legal.
What formulation patents protect competing dantrolene products?
Formulation protection is most relevant to injectable dantrolene. Conventional dantrolene products have historically required preparation before administration. Ryanodex was designed to reduce this burden by using a more concentrated formulation and a smaller amount of sterile water for injection.[2]
A formulation-based product may seek protection for:
- Concentration of dantrolene sodium
- Solubilizing agents
- Reconstitution volume
- Stability characteristics
- Vial configuration
- Administration method
- Preparation-time advantages
Such protection can delay direct copying of a specific formulation, but it does not create exclusivity over dantrolene as an active ingredient. Competitors can continue selling alternative injectable formulations if they avoid valid, enforceable claims.
What patent litigation and Paragraph IV risks affect Dantrium?
Dantrium itself is not primarily exposed to a new wave of Paragraph IV litigation because its foundational patents are old and generic competition is already established. The more relevant litigation risk lies in differentiated injectable products, where manufacturers may challenge formulation or method patents.
Litigation exposure by product
| Product |
Paragraph IV risk |
Current commercial significance |
| Dantrium capsules |
Low as a future event |
Generic competition is already mature |
| Traditional Dantrium IV |
Low |
Market access depends more on supply and contracts |
| Ryanodex-type product |
Higher |
Formulation patents may support branded pricing |
| New dantrolene delivery systems |
Potentially material |
Patent validity and infringement could affect launch timing |
A generic applicant seeking approval for a product with listed patents may file a Paragraph IV certification. The patent holder can then bring infringement litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework.[4] That mechanism is more relevant to newer formulation products than to legacy Dantrium.
Is there biosimilar risk for Dantrium?
No. Dantrium is a chemically synthesized small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act does not apply.
The relevant competitive threats are:
- Abbreviated New Drug Application products
- Therapeutically equivalent oral capsules
- Alternative injectable dantrolene formulations
- Hospital contract substitution
- Products with faster emergency preparation
This distinction matters because the regulatory and litigation framework is Hatch-Waxman generic competition, not the biosimilar pathway.
What licensing deals affect the Dantrium market?
Publicly visible licensing activity has been more relevant to differentiated dantrolene products than to the legacy Dantrium brand. Ryanodex was developed and commercialized by Eagle Pharmaceuticals as a proprietary formulation of dantrolene sodium.[2]
Dantrium’s commercial history has involved ownership and portfolio changes among pharmaceutical companies, but the product has not generated the type of publicly disclosed royalty stream associated with a recently launched specialty drug. Any valuation should therefore treat Dantrium as a mature product asset and separate it from broader company-level licensing revenue.
How does Dantrium compare with Ryanodex?
| Attribute |
Dantrium IV |
Ryanodex |
| Active ingredient |
Dantrolene sodium |
Dantrolene sodium |
| Primary use |
Malignant hyperthermia |
Malignant hyperthermia |
| Product maturity |
Legacy |
Newer differentiated formulation |
| Preparation burden |
Higher for conventional presentation |
Lower |
| Patent value |
Limited legacy protection |
Greater formulation-related value |
| Pricing basis |
Established supply and brand |
Emergency-use convenience and workflow |
| Generic substitution |
Established |
More dependent on formulation and patent status |
| Hospital decision driver |
Availability and familiarity |
Speed, inventory and operational efficiency |
Ryanodex has the stronger product-level differentiation, while Dantrium benefits from historical recognition. If a hospital prioritizes lowest acquisition cost, conventional generic dantrolene may win. If it prioritizes rapid preparation and reduced storage burden, Ryanodex may justify a premium.
What revenue exposure does Dantrium create for manufacturers?
Dantrium’s revenue exposure is concentrated in a small number of institutional and specialty channels. The product does not have the broad prescriber base of a primary-care medicine.
Key revenue drivers
- Operating-room and ambulatory surgery center volume
- Number of facilities maintaining malignant hyperthermia stock
- Hospital group purchasing contracts
- Generic availability
- Drug shortages and back-order events
- Annual contract repricing
- Oral capsule prescription volume
- Product discontinuations or manufacturing transfers
Key downside risks
- Permanent generic price erosion in oral capsules
- Hospital conversion to lower-cost injectable alternatives
- Loss of preferred wholesaler or group purchasing status
- Manufacturing disruption
- Expired inventory caused by low utilization
- Increased adoption of competing rapid-reconstitution products
- Regulatory or quality issues affecting supply
Because malignant hyperthermia treatment is infrequent, demand is relatively inelastic at the facility level but volatile at the unit level. A manufacturer may sell a modest number of units while maintaining a large installed base of hospitals.
What is the outlook for Dantrium’s market?
The Dantrium market should remain stable but low-growth. Demand for dantrolene is supported by the continuing use of triggering anesthetics and hospital requirements for emergency preparedness. Revenue growth is unlikely to come from increased disease prevalence. It must come from pricing, contract wins, product availability or formulation upgrades.
Base-case market outlook
- Oral Dantrium: continued erosion from generic substitution.
- Conventional injectable Dantrium: stable demand with procurement-driven pricing.
- Rapid-reconstitution formulations: stronger pricing potential but patent and substitution risk.
- Total dantrolene market: low unit growth, modest value growth, high sensitivity to supply conditions.
The commercial winner is likely to be the supplier with the best combination of regulatory compliance, manufacturing reliability, hospital distribution and emergency-use convenience.
What generic launch risks exist for Dantrium?
The principal generic launch risk is not a single future launch date. It is ongoing substitution by approved dantrolene products.
A new entrant could pressure prices by offering:
- Lower-cost oral capsules.
- Injectable dantrolene with comparable reconstitution requirements.
- Improved packaging or shelf-life.
- Reliable supply during shortages.
- Direct contracting with hospital systems.
A competitor would still need to meet FDA manufacturing standards and establish distribution in a market where annual demand is relatively small. That limits the incentive for large numbers of entrants, but it also makes supply disruption more consequential.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are moderate. Dantrolene is an established active ingredient, but injectable production requires validated sterile manufacturing, appropriate packaging and dependable quality control.
The main barriers are:
- Sterile injectable manufacturing capacity
- Stability and shelf-life management
- Regulatory compliance
- Inventory economics for low-frequency emergencies
- Hospital qualification and contracting
- Formulation-specific intellectual property
- Distribution reliability
These barriers are stronger for injectable products than for oral capsules. They can support a limited number of durable suppliers even after patent expiry.
Key Takeaways
- Dantrium is a mature dantrolene sodium brand with limited current patent protection.
- The market divides into oral chronic-spasticity products and injectable malignant-hyperthermia products.
- Oral Dantrium faces established generic substitution and persistent price pressure.
- Injectable demand is low-volume but strategically important because hospitals must maintain emergency stock.
- Ryanodex competes through rapid reconstitution and operational convenience rather than a new active ingredient.
- The principal commercial moat is supply reliability, hospital contracting and formulation convenience.
- Dantrium has no biosimilar risk because dantrolene is a small-molecule drug.
- Future financial performance is more likely to reflect stable institutional demand and pricing volatility than prescription-driven growth.
- Public disclosures do not provide a reliable, standalone Dantrium revenue history.
FAQs
Is Dantrium still commercially available?
Dantrium has been marketed as oral dantrolene capsules and as an injectable product, while generic dantrolene products also supply the market. Product availability can differ by formulation, manufacturer and distribution channel.
Is dantrolene a profitable hospital drug?
It can be commercially valuable despite low utilization because hospitals must maintain emergency inventory. Profitability depends on acquisition price, contract position, inventory turnover and supply reliability.
Can a generic company launch dantrolene without challenging Dantrium patents?
For legacy Dantrium products with expired foundational protection, a generic applicant generally competes through the abbreviated approval pathway without facing a meaningful current composition-of-matter patent barrier. Newer formulation products may present separate patent issues.
Does Ryanodex replace Dantrium?
Ryanodex can replace conventional injectable dantrolene in some hospital protocols, but it does not eliminate the broader need for dantrolene. Product selection depends on cost, preparation time, inventory policy and clinical workflow.
What is the largest long-term risk to Dantrium revenue?
The largest risk is continued substitution by lower-cost generic oral and injectable products, compounded by hospital contract losses and adoption of alternative rapid-reconstitution formulations.
References
- U.S. Food and Drug Administration. (2015). Dantrium (dantrolene sodium) capsules prescribing information. FDA.
- U.S. Food and Drug Administration. (2014). Ryanodex (dantrolene sodium) for injectable suspension prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.
